Anti-cd22 single domain antibodies and therapeutic constructs
Номер патента: EP4188952A1
Опубликовано: 07-06-2023
Автор(ы): Cunle Wu, Mehdi Arbabi-Ghahroudi, Risini Weeratna, Scott MCCOMB, Tina Nguyen
Принадлежит: NATIONAL RESEARCH COUNCIL OF CANADA
Опубликовано: 07-06-2023
Автор(ы): Cunle Wu, Mehdi Arbabi-Ghahroudi, Risini Weeratna, Scott MCCOMB, Tina Nguyen
Принадлежит: NATIONAL RESEARCH COUNCIL OF CANADA
Реферат: Herein are provided anti-CD22 single domain antibodies (sdAb) prepared by immunizing a llama with the extracellular domain of the predominant human CD22 isoform. By constructing a library of the heavy chain repertoire generated, VHH antibodies specific to the immunogen were isolated. The 27 example antibodies initially produced comprise CDR1, CDR2, and CDR3 sequences corresponding, respectively to SEQNOs: 1-3, 4-6, 7-9, 10-12, 13-15, 16- 18, 19-21, 22-24, 25-27, 28-30, 31-33, 34-36, 37-39, 40-42, 43-45, 46-48, 49-51, 52-54, 55- 57, 58-60, 61-63, 64-66, 67-69, 70-72, 73-75, 75-78, and 79-81; and related sequences. Also provided are multivalent antibodies comprising any one of the sdAbs, including bispecific T-cell engagers, bispecific killer cell engagers (BiKEs), and trispecific killer cell engagers (TriKEs). Also described are chimeric antigen receptors (CARs) for CAR-T therapy comprising any one of the aforementioned sdAbs. Uses of these molecules in the treatment of cancer are also described.
Anti-cd22 single domain antibodies and therapeutic constructs
Номер патента: CA3187472A1. Автор: Risini Weeratna,Mehdi Arbabi-Ghahroudi,Scott MCCOMB,Cunle Wu,Tina Nguyen. Владелец: NATIONAL RESEARCH COUNCIL OF CANADA. Дата публикации: 2022-02-03.